Compare ILAG & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ILAG | CVKD |
|---|---|---|
| Founded | 1981 | 2022 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 10.3M |
| IPO Year | 2020 | 2022 |
| Metric | ILAG | CVKD |
|---|---|---|
| Price | $3.44 | $3.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 28.2K | ★ 71.7K |
| Earning Date | 04-24-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $3.02 |
| 52 Week High | $7.19 | $14.64 |
| Indicator | ILAG | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 51.26 | 30.46 |
| Support Level | $0.44 | N/A |
| Resistance Level | $3.85 | $5.99 |
| Average True Range (ATR) | 0.33 | 0.45 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 71.33 | 6.21 |
Intelligent Living Application Group Inc focuses on designing and producing affordable, high-quality locksets and smart security systems. The company offers high-quality mechanical locksets and smart locks to its customers. Its product portfolio comprises various ODM indoor and outdoor locksets, such as deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks, which are marketed through brands like Kambo and Bamberg. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Taiwan.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.